title: Anti-inflammatory effects of 17beta-estradiol pretreatment in men after coronary artery surgery.
abstract: OBJECTIVE
  To investigate the anti-inflammatory and hemodynamic effects of 17beta-estradiol in men undergoing elective coronary artery bypass graft surgery (CABG).
  
  
  METHODS
  Prospective, randomized, controlled.
  
  
  METHODS
  Operating room and intensive care unit in a university hospital.
  
  
  METHODS
  Twenty-one men undergoing primary, elective CABG surgery.
  
  
  METHODS
  17beta-estradiol, 2mg, was given orally twice in 14 hours before the operation.
  
  
  RESULTS
  Leukocyte counts, plasma myeloperoxidase, tumor necrosis factor-alpha, interleukin (IL)-6, IL-8, and IL-10 were measured perioperatively. Leukocyte counts were lower in the 17beta-estradiol group than in controls at 6 hours (11.4 +/- 2.0 hours v 15.5 +/- 4.7 hours x 10(9)/L) and 20 hours (11.6 +/- 1.9 hours v 13.6 +/- 2.5 hours x 10(9)/L) after reperfusion (p = 0.03). The release of myeloperoxidase was lower in the 17beta-estradiol group than in controls (5 minutes; 634.4 +/- 213.1 microg/mL v 773.1 +/- 209.3 microg/mL; 4 hours, 305.0 +/- 108.0 microg/mL v 441.3 +/- 191.6 microg/mL; p = 0.02). Systemic vascular resistance index was lower just after cardiopulmonary bypass, and cardiac index was higher postoperatively in the 17beta-estradiol group as compared with controls.
  
  
  CONCLUSIONS
  Pretreatment with 17beta-estradiol can limit leukocyte activation in men after CABG surgery.
authors.affiliation: Division of Cardiovascular Surgery, Department of Anesthesia and Intensive Care, Tampere University Hospital, Tampere, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Wei
authors.forename: P
authors.initials: P
authors.lastname: Kuukasjärvi
authors.forename: S
authors.initials: S
authors.lastname: Kaukinen
authors.forename: J
authors.initials: J
authors.lastname: Laurikka
authors.forename: E
authors.initials: E
authors.lastname: Pehkonen
authors.forename: S
authors.initials: S
authors.lastname: Laine
authors.forename: E
authors.initials: E
authors.lastname: Moilanen
authors.forename: R
authors.initials: R
authors.lastname: Metsänoja
authors.forename: M
authors.initials: M
authors.lastname: Tarkka
mesh_terms: D000284:Administration, Oral; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001026:Coronary Artery Bypass; D016207:Cytokines / Q000097:blood*; D004958:Estradiol / Q000008:administration & dosage* / Q000494:pharmacology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009195:Peroxidase / Q000097:blood; D011292:Premedication; D011446:Prospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D004958:Estradiol; D009195:Peroxidase